Ticker brief
ARGX
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
36
authors 14d
21
crowd 14d
+1.1σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-27 · now -0.10 (−1 bearish … +1 bullish)
Who spoke21
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 4 | +0.46 |
| @scetrader | C | +1.59 | 3 | +0.08 |
| @MartyChargin | C | -0.27 | 3 | +0.48 |
| @Briefingcom | B | +0.50 | 3 | +0.38 |
| @OpenOutcrier | C | · | 3 | +0.23 |
| @SpartanTrading | C | -1.46 | 2 | +0.30 |
| @OzmosiHealth | C | · | 2 | +0.28 |
| @BiopharmIQ | B | · | 2 | +0.40 |
| @fj_nextstage | C | -2.18 | 2 | +0.42 |
| @fwpharma | B | +0.98 | 1 | +0.55 |
| @dangerousteee | C | +1.46 | 1 | +0.70 |
| @doublejtrading | C | -1.82 | 1 | +0.00 |
| @MartinShkreli | B | +1.42 | 1 | -0.10 |
| @HedgeFundTips | B | +0.49 | 1 | +0.10 |
| @IBDinvestors | B | +1.05 | 1 | +0.35 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.15 |
| @akishore | C | -1.38 | 1 | +0.50 |
| @anandragn | C | -1.17 | 1 | +0.25 |
| @StockMKTNewz | C | +0.59 | 1 | +0.40 |
| @DeItaone | B | -0.84 | 1 | +0.40 |
| @financespotnews | C | -3.33 | 1 | -0.10 |
Recent signals30of 36 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @financespotnews | -0.10 | Argenx completes its acquisition of Forte Biosciences and adds FB102. | · | tweet ↗ |
| 2026-08-26 | @semodough | +0.15 | Notes Argenx rose 3.3%, or about $33, during the day. | · | tweet ↗ |
| 2026-08-26 | @OpenOutcrier | +0.40 | Lists analyst upgrades and downgrades; capped at the first six tickers. | · | tweet ↗ |
| 2026-08-26 | @Briefingcom | +0.40 | UBS upgraded ARGX to Buy from Neutral with a $1,400 target. | · | tweet ↗ |
| 2026-08-26 | @DeItaone | +0.40 | Lists multiple equity upgrades and downgrades; output is capped at the first six tickers. | · | tweet ↗ |
| 2026-08-24 | @OpenOutcrier | -0.30 | Recaps positive and negative third-party stock comments from the session. | · | tweet ↗ |
| 2026-08-21 | @BiopharmIQ | +0.30 | Summarizes the week's largest biotech movers and their associated catalysts. | · | tweet ↗ |
| 2026-08-21 | @MartyChargin | +0.65 | Reports a 24% weekly move after a base breakout. | · | tweet ↗ |
| 2026-08-20 | @StockMKTNewz | +0.40 | Lists stocks that reached new 52-week highs today; output is capped at six tickers. | · | tweet ↗ |
| 2026-08-18 | @anandragn | +0.25 | New highs cluster in healthcare, energy and defensives, suggesting money is leaving risk-on growth for safety and cash flow. | · | tweet ↗ |
| 2026-08-18 | @OzmosiHealth | +0.00 | Argenx presented phase 3 autoimmune-myopathy results on August 17. | · | tweet ↗ |
| 2026-08-18 | @semodough | +0.55 | Highlights ARGX strength and says Avoro owns one million shares at an average near $200. | · | tweet ↗ |
| 2026-08-18 | @semodough | +0.75 | Highlights a $13–16 billion 2030–31 sales outlook and speculates about ARGX acquisition targets. | · | tweet ↗ |
| 2026-08-18 | @scetrader | +0.00 | Expects a mixed-to-lower market with rates in focus and semiconductor stocks weaker. | · | tweet ↗ |
| 2026-08-17 | @scetrader | +0.15 | Notes Argenx reached a record after strong Vyvgart data but says the author has become more selective. | · | tweet ↗ |
| 2026-08-17 | @semodough | +0.40 | Details Baird's $932 ARGX target and sum-of-the-parts valuation assumptions | · | tweet ↗ |
| 2026-08-17 | @akishore | +0.50 | Market recap reports multiple discrete analyst, clinical, short-report and earnings events | · | tweet ↗ |
| 2026-08-17 | @fj_nextstage | +0.40 | Lists additions and deletions from IBD50 with technical reasons | · | tweet ↗ |
| 2026-08-17 | @fj_nextstage | +0.45 | Reports IBD exposure, distribution days, breakouts, pivot levels, and two watch candidates | · | tweet ↗ |
| 2026-08-17 | @AponiaAnalytics | +0.15 | Interprets a nonsignificant DM result as likely underpowered despite efficacy comparable to IMNM. | · | tweet ↗ |
| 2026-08-17 | @SpartanTrading | +0.60 | Reports point gains from premarket long ideas after the moves occurred. | · | tweet ↗ |
| 2026-08-17 | @BiopharmIQ | +0.50 | Biotech news list reports FDA acceptance, positive trials, a merger, placement and severe data-related move. | · | tweet ↗ |
| 2026-08-17 | @MartyChargin | +0.20 | Suggests buyers may be supporting ARGX after news, but the question leaves stance uncertain. | · | tweet ↗ |
| 2026-08-17 | @IBDinvestors | +0.35 | Reports Argenx breaking out following another positive development for Vyvgart. | · | tweet ↗ |
| 2026-08-17 | @HedgeFundTips | +0.10 | Presents a broad list of stocks receiving money flows, with details apparently contained in linked media. | · | tweet ↗ |
| 2026-08-17 | @OzmosiHealth | +0.55 | Reports positive Phase 3 ALKIVIA topline results for efgartigimod. | · | tweet ↗ |
| 2026-08-17 | @MartinShkreli | -0.10 | Questions whether ARGX is perversely rising on news; stance is mildly skeptical. | · | tweet ↗ |
| 2026-08-17 | @SpartanTrading | +0.00 | Premarket watchlist names six stocks without stated entry direction. | · | tweet ↗ |
| 2026-08-17 | @Briefingcom | +0.45 | Reports positive market reaction to topline Phase 3 ALKIVIA trial results. | · | tweet ↗ |
| 2026-08-17 | @OpenOutcrier | +0.60 | Argenx announced positive topline Phase 3 ALKIVIA trial results. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.